HRP20050432B1 - Novel medicaments for the treatment of chronic obstructive pulmonary diseases - Google Patents

Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Info

Publication number
HRP20050432B1
HRP20050432B1 HR20050432A HRP20050432A HRP20050432B1 HR P20050432 B1 HRP20050432 B1 HR P20050432B1 HR 20050432 A HR20050432 A HR 20050432A HR P20050432 A HRP20050432 A HR P20050432A HR P20050432 B1 HRP20050432 B1 HR P20050432B1
Authority
HR
Croatia
Prior art keywords
alkyl
treatment
chronic obstructive
obstructive pulmonary
pulmonary diseases
Prior art date
Application number
HR20050432A
Other languages
English (en)
Croatian (hr)
Inventor
Hoenke Christoph
Lustenberger Philipp
Rudolf Klaus
Bouyssou Thierry
Buettner Frank
Konetzki Ingo
Pestel Sabine
Schnapp Andreas
Schollenberger Hermann
Schromm Kurt
Heine Claudia
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050432(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Publication of HRP20050432A2 publication Critical patent/HRP20050432A2/xx
Publication of HRP20050432B1 publication Critical patent/HRP20050432B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20050432A 2002-11-15 2003-11-11 Novel medicaments for the treatment of chronic obstructive pulmonary diseases HRP20050432B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (2)

Publication Number Publication Date
HRP20050432A2 HRP20050432A2 (en) 2006-06-30
HRP20050432B1 true HRP20050432B1 (en) 2012-01-31

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050432A HRP20050432B1 (en) 2002-11-15 2003-11-11 Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Country Status (38)

Country Link
EP (2) EP1562603B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4317138B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101092247B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN101735166A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR041969A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE430569T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003285326B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C016I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0316264B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2506082C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5570670A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1110500T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE10253282A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1562603T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA008665B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP055774A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2326878T7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20050432B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1400011I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL167900A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1562603I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92433I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME00354B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05005081A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY136034A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300650I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO334314B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ540661A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20040694A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL212238B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1562603E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS51607B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1562603T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI343812B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA81276C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004045618A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200502246B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
PT1781298E (pt) * 2004-04-22 2012-02-03 Boehringer Ingelheim Int Combinações farmacêuticas contendo benzoxazinas para o tratamento de doenças respiratórias
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
CA2565243A1 (en) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
BRPI0614410A2 (pt) * 2005-08-15 2011-03-29 Boehringer Ingelheim Int processo para preparação de betamiméticos
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
CN101296700A (zh) * 2005-11-09 2008-10-29 贝林格尔·英格海姆国际有限公司 吸入用气雾剂制剂
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1986644A1 (de) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080142A1 (es) * 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
NZ571429A (en) 2006-04-21 2011-09-30 Novartis Ag Purine derivatives for use as adenosine A2A receptor agonists
US20100222336A1 (en) * 2006-08-07 2010-09-02 Boehringer Ingelheim International Gmbh Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
US20080176901A1 (en) 2007-01-10 2008-07-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
US20100022770A1 (en) * 2007-01-25 2010-01-28 Boehringer Ingelheim International Gmbh Process for the manufacturing of beta mimetics
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
CN102112130A (zh) 2008-06-10 2011-06-29 诺瓦提斯公司 作为上皮钠通道阻滞剂的吡嗪衍生物
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
EA026693B1 (ru) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP6084926B2 (ja) * 2010-09-21 2017-02-22 インテクリン・セラピユーテイクス・インコーポレイテツド 抗糖尿病固体医薬組成物
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
EP2906218B1 (en) * 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
PL3134396T3 (pl) 2014-04-24 2020-04-30 Novartis Ag Pochodne aminopirydyny jako inhibitory 3-kinazy fosfatydyloinozytolu
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
WO2018114887A1 (en) 2016-12-20 2018-06-28 Laboratorios Lesvi, S.L. Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
BR112021024668A2 (pt) 2019-06-10 2022-05-31 Novartis Ag Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
BR112022002569A2 (pt) 2019-08-28 2022-07-19 Novartis Ag Derivados de 1,3-fenil heteroarila substituídos e seu uso no tratamento de doenças
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (de) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Neue Ammoniumverbindungen, ihre Herstellung und Verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200201056A1 (ru) * 2000-04-27 2003-04-24 Бёрингер Ингельхайм Фарма Кг Новые, обладающие продолжительным действием бетамиметики, способ их получения и их применение в качестве лекарственных средств

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (de) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Neue Ammoniumverbindungen, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
BR0316264A (pt) 2005-10-11
BRPI0316264B8 (pt) 2021-05-25
TW200423943A (en) 2004-11-16
LTC1562603I2 (lt) 2016-12-12
BE2014C016I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-03-07
DE10253282A1 (de) 2004-05-27
EA200500715A1 (ru) 2005-12-29
JP2006508140A (ja) 2006-03-09
CY2014032I1 (el) 2015-12-09
HRP20050432A2 (en) 2006-06-30
WO2004045618A2 (de) 2004-06-03
ME00354B (me) 2011-10-10
ES2326878T7 (es) 2014-03-11
ES2326878T3 (es) 2009-10-21
WO2004045618A3 (de) 2004-09-30
UA81276C2 (en) 2007-12-25
PT1562603E (pt) 2009-06-18
EA008665B1 (ru) 2007-06-29
MY136034A (en) 2008-07-31
NL300650I2 (nl) 2017-11-02
NZ540661A (en) 2007-12-21
NO334314B1 (no) 2014-02-03
CN1713914A (zh) 2005-12-28
MXPA05005081A (es) 2005-07-01
AR041969A1 (es) 2005-06-01
JP4317138B2 (ja) 2009-08-19
ECSP055774A (es) 2005-11-22
CO5570670A2 (es) 2005-10-31
CN101735166A (zh) 2010-06-16
NO20052883L (no) 2005-06-14
LU92433I2 (fr) 2014-06-24
CN101817800A (zh) 2010-09-01
PE20040694A1 (es) 2004-11-23
PL212238B1 (pl) 2012-08-31
IL167900A (en) 2013-06-27
MEP53608A (en) 2011-05-10
CA2506082C (en) 2011-06-21
AU2003285326B2 (en) 2009-06-04
EP1562603A2 (de) 2005-08-17
EP1562603B3 (de) 2014-01-08
DK1562603T3 (da) 2009-09-07
CA2506082A1 (en) 2004-06-03
AU2003285326A1 (en) 2004-06-15
KR101092247B1 (ko) 2011-12-12
AR087241A2 (es) 2014-03-12
KR20050075013A (ko) 2005-07-19
EP2025338A1 (de) 2009-02-18
CY2014032I2 (el) 2015-12-09
RS51607B (sr) 2011-08-31
TWI343812B (en) 2011-06-21
NO2014005I1 (no) 2014-03-10
HUS1400011I1 (hu) 2022-02-28
ATE430569T1 (de) 2009-05-15
FR14C0049I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-08-08
PL375270A1 (en) 2005-11-28
SI1562603T1 (sl) 2009-10-31
BRPI0316264B1 (pt) 2019-04-09
RS20050361A (sr) 2007-04-10
FR14C0049I2 (fr) 2015-07-24
EP1562603B1 (de) 2009-05-06
CY1110500T1 (el) 2015-04-29
ZA200502246B (en) 2006-01-25
DE50311502D1 (de) 2009-06-18

Similar Documents

Publication Publication Date Title
HRP20050432B1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
SE0202463D0 (sv) Novel compounds
MY132106A (en) New pyridazin-3(2h)-one derivatives
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
NO20061454L (no) Compounds having CRTH2 antagonist activity
SE0101387D0 (sv) Novel compounds
TW200800970A (en) Novel cycloalkane carboxamides
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
NO20044995L (no) Heterosykliske forbindelser
WO2005051300A3 (en) Bicyclic inhibitors of mek and methods of use thereof
SE0202429D0 (sv) Novel Compounds
DE60333746D1 (de) Thienylverbindungen
ECSP055533A (es) Compuestos de fenilsulfonamida sustituida inhibidores de la producción de beta-amiloide
ATE331711T1 (de) Entzündungshemmende 3-arylthio-3- thiazolylalkylamine
GB0314967D0 (en) Piperazine derivatives
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
RS50229B (sr) Analozi vitamina d3
SE9803773D0 (sv) Compounds
MX2009013003A (es) Derivados de piperidina-amida.
SE0202461D0 (sv) Novel compounds
DE60215918D1 (de) Azofarbstoffe
ATE265423T1 (de) Neue phenylheteroalkylamin-derivate
MXPA04001121A (es) Derivados de fenilo.
SE0102640D0 (sv) Novel compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20181106

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191022

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201102

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211109

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20221107

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20231111